Contact
searchSearch
HMP Global
Login

Myelofibrosis Excellence Forum

Myelofibrosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Andrew Kuykendall, MD
Conference Coverage
Rusfertide Improves Hematocrit Control for Certain Patients With Myeloproliferative Neoplasms
06/03/2025
Andrew Kuykendall
Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses...
06/03/2025
Oncology
Daehyun Lee, MD
Conference Coverage
Pulmonary Hypertension Prevalent Among Patients With Myelofibrosis
06/03/2025
Daehyun Lee,  MD
Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.
Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.
Daehyun Lee, MD, discusses...
06/03/2025
Oncology
Lucía Pérez-Lamas, MD
Videos
Momelotinib Demonstrates Real-World Efficacy, Improved Anemia Symptoms Among Patients With Myelofibrosis
02/07/2025
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of...
02/07/2025
Oncology
John Mascarenhas, MD
Videos
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
01/29/2025
John Mascarenhas, MD
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated...
01/29/2025
Oncology
Prithviraj Bose, MD
Videos
Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis
07/25/2024
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares...
07/25/2024
Oncology
John Mascarenhas, MD
Videos
Examining Real-World Outcomes Among Patients With Myelofibrosis Treated With Pacritinib
07/17/2024
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.
John Mascarenhas, MD, shares...
07/17/2024
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Q&As
Elritercept Well-Tolerated, Demonstrates Potential Efficacy for the Treatment of Patients With Myelofibrosis
07/11/2024
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.
Claire Harrison, MD, FRCP,...
07/11/2024
Oncology
Aaron Gerds, MD
Videos
Novel Updates in Frontline Myelofibrosis Treatment Research
06/25/2024
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.
Aaron Gerds, MD, discusses data...
06/25/2024
Oncology
Aaron Gerds, MD
Videos
Examining Luspatercept Efficacy for Anemia and Transfusion Burden Among Patients With Myelofibrosis
06/24/2024
Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.
Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.
Aaron Gerds, MD, presents...
06/24/2024
Oncology
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine
Videos
Rusfertide Improves Hematocrit Control and Decreases Use of Phlebotomy Among Patients With PV
05/28/2024

Featuring Marina Kremyanskaya, MD, PhD

Featuring Marina Kremyanskaya, MD, Ph...
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
Marina Kremyanskaya, MD, PhD,...
05/28/2024
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use